Riskpilot← Back to searchSign inGet full accessP4Bios AB
ABActiveOrg 5593046567All other professional, scientific and technical activities n.e.c. · NACE 7499Est. 20211-4 employees
Revenue 2025
—
EBITDA margin
—
+80% vs 2024
Equity ratio
99.5%
Financial strength
Net profit 2025
SEK -8K
+80% vs 2024
| Revenue | — | — |
| EBITDA | SEK -8K | +80% |
| Net profit | SEK -8K | +80% |
| Total assets | SEK 407K | -2% |
| Equity | SEK 405K | -2% |
| Employees | — | — |
Legal name
P4Bios AB
Org number
5593046567
Legal form
Aktiebolag
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
1 mars 2021
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva forskning och framtagning av metoder för behandling av olika allvarliga sjukdomar inklusive cancer samt därmed likvärdig verksamhet.
Address
Email
erik.moberg@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | — | — | — |
| Staff expenses | — | — | — | — |
| EBITDA | −4 | −1 | −40 | −8 |
| Depreciation & amort. | −0 | — | — | — |
| EBIT | −4 | −1 | −40 | −8 |
| Net financials | — | — | — | — |
| Profit before tax | −4 | −1 | −40 | −8 |
| Tax | −0 | — | — | — |
| Net profit | −4 | −1 | −40 | −8 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 23 | 22 | 415 | 407 |
| Equity | 21 | 20 | 413 | 405 |
| Long-term debt | 0 | — | — | — |
| Short-term debt | 2 | 2 | 2 | 2 |
| Total debt | 2 | 2 | 2 | 2 |
EBITDA margin
-790000.0%
This company
15.8%
Market median
-5000100% vs market
20222025
Equity ratio
99.5%
This company
38.2%
Market median
+160% vs market
20222025
Return on equity
-1.9%
This company
18.4%
Market median
-110% vs market
20222025
Net profit margin
-790000.0%
This company
8.1%
Market median
-9753186% vs market
20222025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20222025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-03-01 – 2022-06-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Former (2) | ||
| Deputy Board Member | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of P4Bios AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anita Margareta Odénius | Deputy Board Member | 0 companies |
| Erik Gunnar Magnus Moberg | Board of Directors | 0 companies |
| Per Mats Dahlkvist | Board of Directors | 0 companies |
| John Sören Gyll | Deputy Board Member | 0 companies |